Artificial Intelligence: An Underutilized Opportunity for Pharma Leaders

In a new interview with Outsourcing-Pharma, Jeff Elton, CEO of ConcertAI, explains his thoughts on how the drug development and research industry can benefit from the increasing utilization of artificial intelligence (AI) and real-world data (RWD). In drug development, AI can help identify and work around gaps in knowledge of known mechanism pathways and reveal biological redundancies that may thwart the effects of a particular therapeutic intervention. It can also be used to inform clinical trial design.

According to Elton, “We are seeing AI in guiding insights into where and how to deploy the initial early phase trials, even infornming the clinical endpoints of interest and relevance. It is also underpinning the design of clinical studies, each paremeter of the study, how those studies can assure representativeness and coverage of reacial and ethnic sub-populations that may be disproportionately negatively impacted by the disease, and how to assure the statistical power of the study with the minimum of patient participants and sites activated.”

Click here to read the entire interview.

(Source: Outsourcing Pharma, March 14^th, 2022)